Integrated Wealth Concepts’s Iovance Biotherapeutics IOVA Stock Holding History

Integrated Wealth Concepts’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$54.8K	Buy	+13,181	New	+$50.1K	﹤0.01%	3295

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Integrated Wealth Concepts's IOVA Position: Q2 2026 in Review

Integrated Wealth Concepts opened a new position in Iovance Biotherapeutics (IOVA) in Q2 2026: 13,181 shares worth $54.8K. The stake represents ﹤0.01% of the portfolio and ranks #3295 among its holdings.

291 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

Integrated Wealth Concepts held 13,181 shares of Iovance Biotherapeutics worth $54.8K as of Q2 2026.
Iovance Biotherapeutics was a new Integrated Wealth Concepts position in Q2 2026.
Iovance Biotherapeutics made up ﹤0.01% of Integrated Wealth Concepts's portfolio in Q2 2026, its #3295 holding.
291 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Integrated Wealth Concepts's 13F filing for Q2 2026, filed 12 Aug 2026.